Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 115Urinary Bladder Neoplasms 56Carcinoma, Non-Small-Cell Lung 53Cholangiocarcinoma 33Biliary Tract Neoplasms 32Neoplasm Metastasis 30Ovarian Neoplasms 29Lymphoma, Large B-Cell, Diffuse 27Breast Neoplasms 25Neoplasms 24Lung Neoplasms 24Carcinoma, Transitional Cell 23Triple Negative Breast Neoplasms 22Nasopharyngeal Carcinoma 21Colorectal Neoplasms 20Non-Muscle Invasive Bladder Neoplasms 19Recurrence 17Fallopian Tube Neoplasms 16Gallbladder Neoplasms 15Sarcoma 13Bile Duct Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Hodgkin Disease 10Lymphoma 9Adenocarcinoma 9Uterine Cervical Neoplasms 8Stomach Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Nasopharyngeal Neoplasms 6

Interventions

Paclitaxel 15Carboplatin 9liposomal doxorubicin 8Bevacizumab 8pembrolizumab 7Topotecan 6olaparib 4mirvetuximab soravtansine 4Nivolumab 4Cyclophosphamide 4niraparib 3fludarabine 3Gemcitabine 3Drug Therapy 3rucaparib 2ribociclib 2pegfilgrastim 2palbociclib 2oregovomab 2fludarabine phosphate 2Irinotecan 2Hyperthermic Intraperitoneal Chemotherapy 2Fulvestrant 2Cisplatin 2Blood Specimen Collection 21-dodecylpyridoxal 2trastuzumab deruxtecan 1sacituzumab govitecan 1isoquercitrin 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Gemcitabine × 1 year × Clear all
NCT04516447 2026-04-07

MUIR

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 1 Recruiting
172 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Sutro Biopharma, Inc.

Phase 2/3 Terminated
600 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡